Physician profile
Diane Sheree Eakins
NPI 1841765872
$7,930.45
in general payments reported to CMS, 2019-2025
22 companies · $1,486 in 2025
The $1,486 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Registered Nurse) providers received nationally (typical 2025 total: $137).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,428 · 2022: $1,708 · 2023: $1,550 · 2024: $1,758 · 2025: $1,486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,794.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,145.28 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,809.22 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,149.27 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $542.56 | 2021-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $488.30 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $275.95 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $266.69 | 2021-2025 | Lybalvi, Aristada |
| Takeda Pharmaceuticals U.S.A., INC. | $199.74 | 2021-2022 | |
| Axsome Therapeutics, INC. | $193.09 | 2022-2025 | Auvelity |
| Lundbeck LLC | $169.01 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $137.53 | 2022-2025 | Spravato |
| Corium, LLC | $124.19 | 2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $124.02 | 2021-2024 | Austedo Xr |
| Merck Sharp & Dohme LLC | $72.07 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $51.10 | 2023-2024 | Quviviq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $39.59 | 2024 | |
| Eisai INC. | $30.76 | 2021 | |
| Tris Pharma INC | $30.18 | 2025 | Onyda Xr |
| Supernus Pharmaceuticals, INC. | $27.44 | 2024-2025 | Qelbree |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $26.00 | 2023 | Aplenzin |
| Almatica Pharma LLC | $14.39 | 2024 | Loreev Xr |
| Vanda Pharmaceuticals INC. | $14.07 | 2025 | Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Eakins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.